Drugs / IFN-γ positive selected T-cells
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02346617 | Jan 2022 → Dec 2023 | cytomegalovirus infection | Yae-Jean Kim | Withdrawn | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT02007356 | Dec 2014 → Dec 2026 expected | Epstein-Barr virus infection, adenoviridae infectious disease, cytomegalovirus infection, disease related to transplantation | University Hospital, Basel, Switzerland | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IFN-γ positive selected T-cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02346617 ↗ |
| Modality | Cell therapy | “donor-derived pathogen-specific IFN-γ positive T-cells” NCT02007356 ↗ |